(Q40097510)

17 September 2017

Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease (English)

1 reference

17 September 2017

1 reference

1 reference

head and neck carcinoma

1 reference

1

1 reference

17 September 2017

Rozencweig M

2

1 reference

PubMed ID

6153379

17 September 2017

Louie AE

series ordinal

3

1 reference

17 September 2017

1 January 1980

1 reference

17 September 2017

1 reference

17 September 2017

2

1 reference

17 September 2017

3

1 reference

17 September 2017

196-205

1 reference

Clinical trials with bleomycin in lymphomas and in solid tumors

17 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

Cis-diamminedichloroplatinum (II). A new anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Systemic chemotherapy of advanced head and neck malignancies

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Bleomycin (NSC-125066) therapy of responsive solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Chemotherapy prior to local therapy in advanced squamous cell carcinoma of the head and neck: Preliminary assessment of an intensive drug regimen

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Cell proliferation kinetics in five human solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Phase II evaluation of bleomycin.A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Early clinical experience with bleomycin in the United Kingdom in series of 105 patients

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Combination chemotherapy of head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

24-hour infusion of cis-platinum in head and neck cancers

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Treatment of carcinoma of the head and neck with intravenous methotrexate.

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Bleomycin therapy in advanced hodgkin's disease and epidermoid cancers

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Kinetically-based multiple drug treatment for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Weekly administration of cis-diamminedichloroplatinum (II) without hydration or osmotic diuresis

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Bleomycin: Mammalian Cell Lethality and Cellular Basis of Optimal Schedule 2

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

High dose methotrexate as a preoperative adjuvant in the treatment of epidermoid carcinoma of the head and neck. A feasibility study and clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Combination Chemotherapy with cis-Diamminedichloroplatinum (II) and Bleomycin in Tumors of the Head and Neck

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients

1 reference

https://api.crossref.org/works/10.1002%2FHED.2890020305

7 January 2021

Identifiers

DOI

10.1002/HED.2890020305

1 reference

17 September 2017

1 reference

PubMed ID

6153379